Zhonshan Ophthalmic Centre
Guangzhou, Guangdong, 510000, China
NCT Number: NCT04421300
The objective of the study is to evaluate the effectiveness of laughter therapy in relieving the symptoms of dry eye disease.
Looking for future studies?
Notify Me18 year–45 year
All sexes
Interventional
Not applicable
Guangzhou, Guangdong, 510000, China
The study is designed to: Test the hypothesis that smile exercise is an effective treatment for Dry Eye Disease (DED) . Better understand the status of emotion, quality of sleep and life in DED patient by describing and evaluating a comprehensive set of features and treatment over 2 months of observation in a well-characterized group of patients.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
i). acute allergic conjunctivitis ii). infection (e.g. bacterial, viral, protozoan or fungal infection of the cornea, conjunctiva, lacrimal gland, lacrimal sac or eyelids) iii). inflammation (e.g., retinitis, macular inflammation, choroiditis, uveitis, scleritis, episcleritis, keratitis)
Launch the "smile face recognition" APP on smart phone, after user guidance and pretest, a smile exercise will display on the phone, while facing the front camera on the phone, participant will do an exercise emphasizing facial movements, as exaggerated as possible. The exercise last for 8 weeks and 4 times a day
0.1% sodium hyaluronate, 4 times a day, the time is in the morning, lunchtime, afternoon and evening. the interval between two training time is 2 hours, 1 hour before and after can be added or subtracted by users, 8 weeks.
Time frame: 12 weeks
OSDI scores from 1, 2, 4, 6, 8, 10 and 12 weeks minus values from baseline. OSDI scores range from 0 to 100, score 0 indicating no ocular discomfort and higher scores indicating greater symptom severity. The minimal clinically significant change is 10 points.
Time frame: 12 weeks
Proportion of participants with at least 10 points decreased from baseline in Ocular Surface Disease Index (OSDI).
Time frame: 12 weeks
LLT from 1, 2, 4, 6, 8, 10 and 12 weeks minus values from baseline among eyes that qualified for the study. The interferometer LLT measurement is a non-invasively and objectively method that produces numeric value. The range of the value is 0-100+; lower value indicates thinner lipid layer.
Time frame: 12 weeks
In this measurement, NI-BUT is measured using the keratography machine. NI-BUT is recorded as the number of seconds that elapse between the last blink and the appearance of the first dry spot in the tear film. Change is record as the values at 1, 2, 4, 6, 8, 10 and 12 weeks minus values at baseline visit. Possible range of score is 0->20. Lower values indicate greater severity.
Time frame: 12 weeks
Assessment of the tear film meniscus is a quantitative measurement of tear film quantity. In this measurement, TMH is measured using the keratography machine. Change is the values at 1, 2, 4, 6, 8, 10 and 12 weeks minus values at baseline visit.
Time frame: 12 weeks
Corneal Flourescein Staining Score from 1, 2, 4, 6, 8, 10 and 12 weeks minus values from baseline visit among eyes that quality that qualified for the study. Possible range of scores is 0-15; higher scores indicate more severe.
Time frame: 12 weeks
Medical Outcomes from study 20-Item Self-Rating Anxiety Scale. This scale range is 0-100 with lower scores indicating better self-reported mental health. Change is the score at 4, 8 and 12 weeks minus the score at baseline visit.
Time frame: 12 weeks
Medical Outcomes from study 20--Item Self-Rating Depression Scale. This scale range is 0-100 with lower scores indicating better self-reported mental health. Change is the score at 4, 8 and 12 weeks minus the score at baseline visit.
Time frame: 12 weeks
A 4-item scale designed to measure subjective happiness. Each of item is completed by choosing one of 7 options that finish a given sentence fragment. Change is the score at 4, 8 and 12 weeks minus the score at baseline visit.
Time frame: 12 weeks
Change is the score at 4, 8 and 12 weeks minus the score at the baseline visits. Scores for each question range from 0 to 3, and the total PSQI scores range from 0 to 100.
Time frame: 12 weeks
Medical Outcomes from study 36-Item Short Form Health Survey (SF-36) Physical Health Subscale. Subscale range is 0-100, with higher scores indicating better self-reported physical health-related quality of life. Change is the score at 4, 8 and 12 weeks minus the score at baseline visit.
Time frame: 12 weeks
Medical Outcomes from study 36-Item Short Form Health Survey (SF-36) Mental Health Subscale. Change is the score at 4, 8 and 12 weeks minus the score at baseline visit.
Time frame: 12 weeks
Change in levels of tear cytokines (mainly in inflammation cytokines, such as iL-17, TNF-alpha, etc.,). Change is the values from 8 and 12 weeks minus the the score at baseline visit.
Time frame: 12 weeks
Lid margin abnormalities were scored from 0 to 4 Change in lid margin abnormalities is the score from 4, 8 and 12 weeks minus the score at baseline visit.
Time frame: 12 weeks
To evaluate meibum quality,five glands of the central part of the upper lid were assessed on a scale of 0-3 for each gland (total score range, 0-15).Change is the total score from 4, 8 and 12 weeks minus the score at baseline visit.
Time frame: 12 weeks
The score of meibomian gland expressibility is range from 0-3. Change is the total score from 4, 8 and 12 weeks minus the score at baseline visit.
Time frame: 12 weeks
Tear film break up time from1, 2, 4, 6, 8, 10 and 12 weeks minus values from baseline visit.
Time frame: 12 weeks
Change in Meibomian gland structure measured using the keratography machine. Change is the score from 8 and 12 weeks minus the values at baseline visit
Zhongshan Ophthalmic Center, Sun Yat-sen University
Other
Clinical Efficacy of Smile Exercise Versus 0.1% Hyaluronic Acid Sodium Eye Drops for Dry Eye Symptoms in Patients With Dry Eye Disease: a Randomized, Controlled, Non-inferiority Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05201170
Conjunctival Diseases, Corneal Diseases
Glendale, California, United States
View Trial DetailsNCT05918406
Conjunctival Diseases, Conjunctivitis
Edison, New Jersey, United States
View Trial DetailsNCT03925727
Conjunctival Diseases, Conjunctivitis
Phoenix, Arizona, United States
View Trial DetailsNCT02970799
Conjunctival Diseases, Conjunctivitis
View Trial Details